Reported 1 day ago
Elutia has agreed to sell its EluPro and CanGaroo bioenvelopes to Boston Scientific for $88 million in cash. This move allows Elutia to strengthen its financial position by eliminating debt and funding new product developments, including NXT-41 and NXT-41x. The EluPro and CanGaroo products focus on enhancing tissue regeneration and healing, with the transaction expected to finalize in Q4 2025.
Source: YAHOO